# Fasting Study of Olanzapine Tablets 20 mg and Zyprexa® Tablets 20 mg

> **NCT00647972** · PHASE1 · TERMINATED · sponsor: **Mylan Pharmaceuticals Inc** · enrollment: 32 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Olanzapine Tablets 20 mg
- **DRUG:** Zyprexa® Tablets 20 mg

## Key facts

- **NCT ID:** NCT00647972
- **Lead sponsor:** Mylan Pharmaceuticals Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-05
- **Primary completion:** 2003-05
- **Final completion:** —
- **Target enrollment:** 32 (ACTUAL)
- **Why stopped:** during Period 1 due to numerous orthostatic AEs that occurred. Subsequently, RLD was reduced to 5 mg due to safety concerns.
- **Last updated:** 2024-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00647972

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00647972, "Fasting Study of Olanzapine Tablets 20 mg and Zyprexa® Tablets 20 mg". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00647972. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*